CHF164.10
0.06% day before yesterday
SIX Swiss Exchange, Dec 23, 05:31 pm CET
ISIN
CH1335392721
Symbol
GALD
Index

Galderma Stock price

CHF164.10
+14.40 9.62% 1M
+52.80 47.44% 6M
+63.46 63.06% YTD
+65.75 66.85% 1Y
+111.10 209.62% 3Y
+111.10 209.62% 5Y
+111.10 209.62% 10Y
+111.10 209.62% 20Y
SIX Swiss Exchange, Closing price Tue, Dec 23 2025
-0.10 0.06%
ISIN
CH1335392721
Symbol
GALD
Index
Industry

New AI Insights on Galderma Insights AI Insights on Galderma

How does the company make money?
Who are the company’s main competitors?
What are the key opportunities and risks?
How is the company managed?

Key metrics

Basic
Market capitalization
CHF38.5b
Enterprise Value
-
Net debt
-
Cash
-
Shares outstanding
-
Valuation (TTM | estimate)
P/E
131.3 | 66.1
P/S
10.4 | 9.2
EV/Sales
- | -
EV/FCF
-
P/B
-
Dividends
DPS
CHF0.15
Yield 1Y | 5Y
0.1% | 0.0%
Growth 1Y | 5Y
100.0% | -
Payout 1Y | 3Y
0.0% | 0.0%
Increased
1 Year
Financials (TTM | estimate)
Revenue
CHF3.7b | CHF4.2b
EBITDA
CHF839.0m | CHF964.4m
EBIT
CHF595.4m | CHF816.9m
Net Income
CHF298.1m | -
Free Cash Flow
CHF578.0m
Growth (TTM | estimate)
Revenue
- | 19.3%
EBITDA
- | 26.3%
EBIT
- | 53.5%
Net Income
- | -
Free Cash Flow
-
Margin (TTM | estimate)
Gross
69.2%
EBITDA
22.7% | 23.1%
EBIT
16.1%
Net
8.1% | -
Free Cash Flow
15.6%
Financial Health
Equity Ratio
61.7%
Return on Equity
3.0%
ROCE
-
ROIC
-
Debt/Equity
-
More
EPS
CHF1.3
FCF per Share
-
Short interest
-
Employees
-
Rev per Employee
-
Show more

Is Galderma a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,079 stocks worldwide.

Galderma Stock Analysis

Unlock Scores for Free

Analyst Opinions

20 Analysts have issued a Galderma forecast:

16x Buy
80%
4x Hold
20%

Analyst Opinions

20 Analysts have issued a Galderma forecast:

Buy
80%
Hold
20%

Financial data from Galderma

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
3,698 3,698
-
100%
- Direct Costs 1,139 1,139
-
31%
2,560 2,560
-
69%
- Selling and Administrative Expenses 1,594 1,594
-
43%
- Research and Development Expense 181 181
-
5%
839 839
-
23%
- Depreciation and Amortization 244 244
-
7%
EBIT (Operating Income) EBIT 595 595
-
16%
Net Profit 298 298
-
8%

In millions CHF.

Don't miss a Thing! We will send you all news about Galderma directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Galderma Group AG engages in the provision of science-based premium dermatology solutions. The firm is also involved in delivering a synergistic portfolio of flagship brands spanning the full spectrum of the fast-growing self-care dermatology market. The company was founded in 1981 and is headquartered in Zug, Switzerland.

Head office Switzerland
CEO Flemming Ørnskov
Website www.galderma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today